Matches in Nanopublications for { ?s ?p "[On August 2011, a small molecule inhibitor against ALK, crizotinib, was approved for therapy against NSCLC with ALK translocations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP8481.RAY1dFhLX6f_bq_jxzb7DU61oUU_rO4ponsIST4o72WiA130_assertion description "[On August 2011, a small molecule inhibitor against ALK, crizotinib, was approved for therapy against NSCLC with ALK translocations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8481.RAY1dFhLX6f_bq_jxzb7DU61oUU_rO4ponsIST4o72WiA130_provenance.
- NP8492.RAayBunMeUeXkICoOqbwiL5Ww3FaVeD5YQZMkmEDn7wLU130_assertion description "[On August 2011, a small molecule inhibitor against ALK, crizotinib, was approved for therapy against NSCLC with ALK translocations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8492.RAayBunMeUeXkICoOqbwiL5Ww3FaVeD5YQZMkmEDn7wLU130_provenance.
- NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_assertion description "[On August 2011, a small molecule inhibitor against ALK, crizotinib, was approved for therapy against NSCLC with ALK translocations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_provenance.